Skip to content

Released Nov 5, 2020, after the close

10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051279

Q3 2020 · 10-Q
Revenue$38.00K−77.9% vs Q3 2019−25.5% vs Q2 2020
Net Income-$18.90MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.86N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$19,020,000N/M
Operating Cash Flowderived-$21,264,000N/M
Free Cash Flowderived-$21,315,000N/M
Margins · derived
Operating margin-50052.6%−39596.2 pt vs Q3 2019
Net margin-49736.8%−39446.1 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$38.00K$172.00K$658.00K$597.00K
Net Income-$18.90M-$17.70M-$10.46M-$9.84M
EPS Diluted-$0.86-$0.95-$0.60-$36.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR